Waisman Y, Rachmel A, Metzker A, Wielunsky E, Nitzan M, Rotem A, Steinherz R
Department of Pediatrics, Beilinson Medical Center, Petah Tiqva, Israel.
Pediatr Dermatol. 1989 Sep;6(3):226-8. doi: 10.1111/j.1525-1470.1989.tb00823.x.
We cared for twin females with severe lamellar exfoliation of the newborn (collodion babies) and a family history of death of two brothers at age 3 months. The twins were given a controlled trial of etretinate (Ro 10-9359, Tigason) after not responding to other therapeutic modalities. One of the infants received 1 mg/kg body weight of the drug for 24 hours, while her identical twin sister did not have the medication. Monthly skin biopsies taken from both patients during nine months of therapy did not demonstrate any histologic difference under light microscopy. The clinical course in both infants was basically the same. Etretinate plasma level measurements proved that the drug was absorbed from the gastrointestinal tract. We conclude that in the very severe forms of congenital lamellar ichthyosis, oral retinoids may fail to produce any beneficial effects.
我们照料了两名患有严重新生儿板层状鱼鳞病(胶样婴儿)的孪生女性,她们有家族史,两名兄弟在3个月大时死亡。这对双胞胎在对其他治疗方式无反应后,接受了依曲替酯(Ro 10 - 9359,银屑灵)的对照试验。其中一名婴儿接受了24小时1毫克/千克体重的药物治疗,而她的同卵双胞胎姐妹未接受该药物治疗。在九个月的治疗期间,每月从两名患者身上采集的皮肤活检标本在光学显微镜下未显示出任何组织学差异。两名婴儿的临床病程基本相同。依曲替酯血浆水平测量证明该药物可从胃肠道吸收。我们得出结论,在非常严重的先天性板层状鱼鳞病中,口服维甲酸可能无法产生任何有益效果。